Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Some Research Resources for Drug Safety and Warnings Information

August 17, 2021 By Law Offices of Thomas J. Lamb, P.A.

For various reasons, one may be interested in finding drug safety and side effects warnings information. Here are three reliable research resources from the FDA which will get you started: Drugs@FDA: FDA-Approved Drugs from the U.S. Food and Drug Administration For prescription brand-name drugs, Drugs@FDA typically includes the most recent … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug safety, side effects

Limbrel Medical Food Product for Osteoarthritis Removed from the Market

January 12, 2018 By Law Offices of Thomas J. Lamb, P.A.

Background Limbrel (flavocoxid) is an anti-inflammatory agent comprised mostly of flavonoids such as baicalin and catechin that is prescribed to manage the metabolic processes associated with osteoarthritis. This supplement has traditionally been classified and marketed as a "medical food," which is defined by the Orphan Drug Act as: "a food … [Read more...]

Filed Under: Unsafe Drugs Tagged With: DILI, drug-induced liver injury, FDA, flavocoxid, hypersensitivity pneumonitis, limbrel, medical food, Pancreatitis, recall, side effects

Pancreatic Cancer Lawsuits Reinstated for Incretin-Based Diabetes Drugs

January 2, 2018 By Law Offices of Thomas J. Lamb, P.A.

Background Among the several different types of therapies indicated for treating type 2 diabetes are increatin mimetics.  The medications approved by the FDA that fall into this class of drugs are: Byetta (exenatide) Bydureon (exenatide) Januvia (sitagliptin) Janumet (sitagliptin) Victoza (liraglutide) Previous scientific … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Bydureon, Byetta, drug injury lawsuits, increatin mimetics, incretin-based diabetes drugs, Janumet, Januvia, new trials incretin therapy diabetes drugs, Pancreatic Cancer, side effects, Victoza

Risk of Lower Limb Amputations Doubled with Invokana and Invokamet Use

May 17, 2017 By Law Offices of Thomas J. Lamb, P.A.

As of yesterday, May 16, 2017, the FDA issued a Drug Safety Communication regarding an increased risk of leg and foot amputations due to use of popular diabetes drugs Invokana, Invokamet, and Invokamet XR, which contain canagliflozin. These drugs belong to the sodium glucose cotransporter 2 (SGLT2) inhibitor class, and are the subjects of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, canagliflozin, dapagliflozin, drug injury, EMA, empagliflozin, Farxiga, FDA, foot amputations, Invokamet, Invokana, Jardiance, leg amputations, sglt2 inhibitors, side effects, toe amputations, Xigduo, xigduo xr

Could Beta-Blocker Use in Pregnant Women Cause Fetal Heart Defects?

April 19, 2017 By Law Offices of Thomas J. Lamb, P.A.

On April 3, 2017, updated results from the National Birth Defects Prevention Study (NBDPS) were released and published in the article "Maternal Antihypertensive Medication Use and Congenital Heart Defects" (Abstract only). This study found that there was a statistically significant association between β-blocker use in pregnant women and fetal … [Read more...]

Filed Under: Unsafe Drugs Tagged With: american heart association, antihypertensive drugs, atenolol, beta-blockers, cardiovascular malformations, coarctation of the aorta, congenital heart defects, drug side effects, fetal heart problems, Hemangeol, hypertension, hypertension drugs, Inderal, Innopran, JAMA, Lopressor, metoprolol, National Birth Defects Prevention Study, perimembranous ventricular septal defect, propranolol, pulmonary valve stenosis, randate (labetalol), secundum atrial septal defect, side effects, Tenormin, Toprol

What’s in a Name? Debate on What to Call Novel Oral Anticoagulants

September 30, 2016 By Law Offices of Thomas J. Lamb, P.A.

Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis.  The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, antidotes, bleeding events, blood thinners, DOAC, drug injury, Eliquis, FDA, Gastrointestinal (GI) Bleeds, hemorrhagic strokes, heparin, increased risks, intracranial hemorrhages, NOAC, ODI, Pradaxa, reversal agents, safety warnings, Savaysa, side effects, SODA, TSOAC, warfarin, Xarelto

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.